In November 1996, word reached the University of Washington that Philip Fialkow and his wife, Helen, had died while trekking in Nepal. Over a 30-year period, Dr Fialkow and his colleagues used the cellular mosaicism resulting from X-chromosome inactivation in females as a marker system to investigate the clonal development of human hematopoietic disorders. This review discusses the impact that these studies have had on our understanding of hematopoietic stem cell relationships and the pathogenesis of human neoplasia in general. To appreciate the special role played by studies on clonality, it is necessary to consider how little was known about the origin of leukemias and myeloproliferative disorders and the limited techniques available for their study in the early to mid 1960s. Dr Fialkow and his coworkers were the first to show that myeloproliferative disorders and acute myelogenous leukemias (AML) are clonal diseases at the time of diagnosis and to elucidate the level of differentiation manifested by the originating cell type. Although the myelodysplastic disorders were found to involve a pluripotent stem cell, heterogeneity was found in the level of stem cell involvement in AML. Evidence was obtained to support a multistep pathogenesis of these diseases as well as a clonal but cytogenetically normal stage in some cases of Ph-positive chronic myelogenous leukemia, AML, acute lymphoblastic leukemia and myelodysplasia.
Introduction
The question of whether a cell proliferation is monoclonal or polyclonal is relevant to understanding the underlying etiology of the condition. If a tissue is responding appropriately to an exogenous stimulus an increase in cell number usually results from polyclonal expansion of the target cells. Examples of this occurrence include granulocytosis or lymphocytosis in response to an infection, erythrocytosis secondary to hypoxemia or polyclonal neoplasia secondary to viral transformation of multiple target cells in immunodeficient individuals. On the other hand, if a cell gains an advantage over its relatives, for example by increased proliferative capacity (life span), loss of dependence on growth factors, or escape from normal cell cycle control, it may develop into a clone. Neoplastic disorders are almost always monoclonal. In addition to providing information about the disease state at the time of presentation, delineating clonal relationships between cells can shed light on events that take place earlier in the course of disease and events that occur with progression of disease. The clonal relationships of different cell types present in a 
Historical perspective
It is now 'common knowledge' that the myeloproliferative disorders and leukemias have a clonal development. However, in the early 1960s, the clonal nature of these and other neoplasms had not been shown. The initiating event for these disorders was and, for the most part, is still unknown. There were speculations regarding the role of ionizing radiation, chemical carcinogens and hereditary factors; observations from animal models supported the possibility of a viral cause for some leukemias (reviewed in Refs 1 and 2). If neoplasms arose by simultaneous events in multiple cells exposed to an exogenous agent or if an affected cell could recruit neighboring cells to proliferate by hormonal or other influences, the neoplasm would be polyclonal at the time of clinical diagnosis.
Intrinsic markers for investigation of clonal relationships
The ability to detect monoclonality in a cell population requires a marker system that enables the progeny of different cells to be recognized. Some cellular markers are intrinsic to a cell population, arising either during normal differentiation or as part of the disease process. For instance, cell surface associated immunoglobulin (Ig) markers such as the or light chain or idiotypes and T cell receptors (TCR) can be used to evaluate lymphoid neoplasms. Using Igs as markers, multiple myeloma was the first neoplastic disease demonstrated to have a clonal development. 3 At one time these markers could only be evaluated by immunofluorescence of the proteins synthesized by relatively mature B cells. Although it is now possible to identify specific DNA rearrangements of the Ig-encoding and TCR subunit genes (eg Refs 4 and 5), these only occur in cells committed to B or T lymphoid origin, respectively, so their usefulness as markers remains limited.
Somatic cytogenetic alterations are also useful intrinsic markers to identify clones and to follow disease progression. Since the first squash preparations of human cells, it had been observed that solid tumors often had very abnormal chromosome contents. 6 It is now known that nonrandom cytogenetic abnormalities characterize many hematopoietic neoplasms. However, in the 1960s, cytogenetics remained an unsophisticated field. Until 1956 there was no consensus regarding the correct number of chromosomes in human cells. 7 In unbanded chromosome preparations, the usually diploid cells of leukemias did not appear different from their normal 109 counterparts; even when abnormalities were seen, they seemed unique to that individual. 8 In 1960, Nowell and Hungerford 9 published their observation of an abnormally small chromosome in peripheral blood cells from two patients with chronic myeloid leukemia (CML). This change in size could only be appreciated because it affected one of the smallest chromosomes in the human complement. Interestingly, both patients were male and the first interpretation was that the abnormal chromosome was a Y chromosome. Nowell and Hungerford could not explain what might be seen in cells from females with CML. It was soon recognized that this chromosome, now named the Philadelphia chromosome (Ph 1 ) for the city in which they worked, was a small autosome, number 21 or 22. 10, 11 Not until the development in the late 1960s and early 1970s of techniques for differentially banding regions of the chromosomes could the individual chromosomes be distinguished within each group. 12, 13 In 1973, Ph 1 was finally recognized as a translocation between chromosomes 9 and 22 14 and in the same year t(8;21)(q22;q22) became the second consistent cytogenetic alteration in human leukemia to be identified as a translocation. 15 Even then, the significance of the cytogenetic abnormality was not understood. Some thought Ph 1 might be an artifact of chemotherapy or in vitro culture. 16 The possibility that erythrocytes and megakaryocytes also contained the Ph 1 was suggested by its presence in all dividing metaphase cells in marrow from untreated cases, including some iron-containing cells. [17] [18] [19] This led to the hypothesis that the disease might arise in a precursor cell common to the myeloid, erythrocytic and megakaryocytic lineages. However, even if an abnormality was recognized by microscopic studies, it did not constitute proof that all leukemic cells had the abnormality, nor that all lineages were represented in the mitotic fraction. Perhaps there were other 'clones' that were not proliferating as quickly (ie what was seen was a subclone that might not comprise the majority of the tumor) or abnormal mitoses spread so poorly that they were not chosen for karyotyping or were impossible to analyze. To substantiate and extend these observations it was necessary to overcome the limitations of the intrinsic markers available at the time.
X-inactivation mosaicism and other extrinsic markers Extrinsic marker systems utilize cellular mosaicism that is completely independent of the disease being studied and is not restricted to a certain cell lineage. For example, cytogenetics can be used to distinguish different cell populations in individuals with Turner or Klinefelter syndrome who are mosaic for XX or XY and XO cells or XXY and XY cells, respectively. The usefulness of the system is limited by the rarity of individuals with both neoplasia and constitutional chromosomal mosaicism.
The mosaicism created by X chromosome inactivation in females is much more widely applicable. Although this process has been shown to be quite complex (reviewed in Ref. 20) , the Lyon hypothesis 21 underlying the use of the X-linked enzyme glucose-6-phosphate dehydrogenase (G6PD) as a marker of clonality is still valid in most circumstances. Early in embryogenesis regions of all but one X chromosome are inactivated in each cell containing two or more X chromosomes and the activation status is stably transmitted to the daughter cells during mitosis. The choice of maternal vs paternal X chromosome for inactivation is random, although in the presence of recessive mutations or X-autosome translocations there may be subsequent selection in favor of cells bearing a specific X chromosome in the active state in certain tissues (eg . More recently, rare families segregating extremely skewed inactivation patterns as an inherited trait have been described, [25] [26] [27] with evidence in one case implicating a mutation in the X inactivation center. 25 There are many G6PD variants, some of which can be distinguished from the common B type by electrophoresis. The G6PD variants A and A− occur in 30-40% of the black population. The observation that human females who are heterozygous for a G6PD variant are mosaic, with some cells stably producing the usual form and other cells only producing the variant form, was first published by Davidson et al 28 in 1963. The G6PD X-inactivation mosaicism system was first applied to the study of clonality in human tumors in 1964 by Gartler and Linder. At the University of Washington, Stanley Gartler, a geneticist, was interested in clonal patch size in tissues and David Linder, a pathologist, was interested in the single cell origin of tumors. They recognized that the presence of normal cells might mask the ability to detect a clonal proliferation; they chose to study uterine leiomyomas because this type of tumor can be separated easily from surrounding tissue. Indeed, these studies showed that individual uterine leiomyomas are clones 29, 30 and that even in samples as small as 1 mm 3 pure patches were not detectable in normal tissues. 31 During this time, Philip Fialkow was completing a fellowship in Medical Genetics at the same institution. He became interested in extending this approach to study other human neoplasia, initially by addressing the questions generated by the identification of the Ph 1 chromosome. Subsequently the implication of Epstein-Barr virus (EBV) in the etiology of Burkitt's lymphoma 32 provided the impetus for studying the clonal nature of these tumors at initial diagnosis and recurrence. Despite the infection of many B lymphocytes, initial Burkitt's tumors were found to be clonal and recurrences after short remissions belonged to the same clone. 33 Only after longer remissions was recurrent disease in some cases unrelated to the original clone. 34 Normal blood samples from G6PD heterozygous patients with tumors provided a substantial body of control data that also proved useful in the ongoing hematologic studies.
Studies on myeloproliferative and myelodysplastic disorders

Chronic myelocytic leukemia
In the mid 1960s it was not known whether the histologic evidence of multilineage involvement in myeloproliferative disorders resulted from an abnormality in a multipotent stem cell or a committed stem cell for the predominant cell type. In the latter case, the committed stem cell or its progeny would affect the behavior of the other lineages. The first hematologic disorder studied by Dr Fialkow and his colleagues was chronic myelocytic leukemia (CML).
They asked three questions: (1) Does it have a clonal origin? (2) What kind of cell is involved? (3) What is the relationship between the cells in remission and those in acute phase? These questions proved to be applicable to the study of other hematopoietic disorders.
The relative activities of G6PD A and B in separated erythrocytes and granulocytes from three heterozygous women with CML were compared to cultured skin fibroblasts. The finding of a single G6PD type in the blood cells but both A and B type G6PD in the normal tissue control corroborated the suggestions based on cytogenetic observations that CML has a clonal origin and provided evidence that the malignant transformation occurs in a stem cell common to both the erythrocytic and granulocytic lineages. 35 By 1973 only one additional patient had been studied. The difficulty of ascertaining heterozygous patients with rare diseases necessitated establishing an extensive network of collaborators throughout the United States and Africa. By 1991 a total of 41 G6PD heterozygous patients with CML had been included in the studies. The same single G6PD found in the granulocytes was always present in red cells, platelets, monocytes and macrophages, demonstrating that CML involves a multipotent stem cell. 36, 37 This still left the question of the relationship between the stem cell for lymphocytes and the stem cell for the multipotent myeloid stem cell. Although most blast crises are myeloid, blast crises with B or T lymphoid characteristics also occur (eg Refs 38 and 39). Blast crisis cells are Ph-positive. However, cytogenetic investigations during chronic phase generally failed to detect the Ph chromosome in lymphocytes. Regardless of the method used to separate lymphocytes from blood, the overwhelming preponderance of myeloid precursors in CML interferes with most protocols. Studies on lymphocytes obtained by a multistep physical separation followed by antigen-receptor fractionation 40 suggested that T cells were not clonal during hematologic remission but were clonal during times of poor control, 41 whereas B cells were clonal at all times. There were some difficulties in interpreting the B cell data. These cells are relatively poor in G6PD and only 40-50% of them showed Ig synthesis. Therefore, it was necessary to confirm and extend these results using cultured cells. G6PD and cytogenetics were analyzed in EBV-transformed lymphoid lines established from a patient whose CML clone produced type B G6PD. The finding that nine lines were Ph-positive proved that the CML stem cell is capable of differentiating to B lymphocytes. 42 Expression of G6PD types in the remaining 63 lines was significantly skewed toward the type found in the leukemic clone. An additional observation was that eight of 33 lymphoid lines expressing the leukemic G6PD type showed karyotypic abnormalities, whereas all of the 14 type A lines had normal karyotypes. Similar results were obtained in a study of 14 additional G6PD-heterozygous women with CML. 43 Ph-positive lymphoid lines were recovered from three of these women, in one case comprising the great majority of independently developed lines (90 of 98). In five patients there was a statistically significant excess of Ph-negative lines expressing the G6PD type exhibited by the CML clone. In contrast, no case showed an excess of lines expressing the opposite G6PD. From their data, Martin, Najfeld and Fialkow 44 put forth a hypothesis in 1982 that is still viable: in at least some patients a cytogenetically normal but genetically unstable clone proliferates and in this population of abnormal but not frankly malignant cells the distinct chromosome change occurs (Figure 1 ). These cells thereby gain great selective advantage and specific leukemic properties. The observation that Ph 1 occasionally arises late in the course of Phnegative CML, [45] [46] [47] myelodysplastic syndromes [48] [49] [50] [51] or acute leukemia supports this hypothesis. [52] [53] [54] [55] In contrast, it is possible that some cases of Ph-negative or mixed blast crisis following Ph-positive CML 56, 57 occur when a coexisting subclone gains dominance over the Ph-positive chronic phase cells. Although the conclusions of the earlier studies predated the availability of DNA correlation, the more recent studies have included evaluation of the bcr-abl fusion transcript.
The observation that some Ph-positive B lymphoid lines produced and others produced chains provided evidence that immunoglobulin light chain expression was not restricted in progeny of the CML stem cell in chronic phase. 42 These B lymphocytes are able to contribute to antibody diversity. In contrast, in lymphoid blast crisis only a single Ig type was found in the few patients in whom the blast cells expressed Ig. [58] [59] [60] Therefore, there is an evolutionary step between the Ph-positive B cells in chronic phase and those in blast crisis.
Studies with G6PD and cytogenetics provide an explanation for lymphoid blast crises and give evidence that myeloid and lymphoid cells derive from a common stem cell that is involved in CML. It is intriguing to conclude that the chronic phase CML stem cell clone produces an overabundance of abnormal myeloid components of all levels of maturation while producing platelets, red cells and lymphocytes that continue to function appropriately and are not overtly leukemic.
Other myeloproliferative disorders
The myeloproliferative disorders (MPD) are characterized by abnormal proliferation of marrow cells. In each, one cell type predominates, but there is evidence that all the other marrow cell types are also proliferating abnormally to a lesser extent. 61 The same questions asked regarding stem cell characterization in CML were then directed toward polycythemia vera (PV). Is it a clonal process and if so, is a multipotent stem cell or a committed red blood cell precursor involved? Circulating erythrocytes, granulocytes and platelets were found to have a clonal G6PD phenotype in both patients studied. 62 In addition, the role of the defined growth factor erythropoietin (epo) in the abnormal red cell proliferation was investigated. G6PD had been used to prove the clonal nature of individual erythroid colonies derived from cells plated at low density. 63 Subsequently, granulocyte/macrophage and mixed colonies of erythroid, myeloid and megakaryocytic cells plated with appropriate cytokines were shown to be clonally derived as well. 64, 65 Erythroid colonies grown from bone marrow in the absence of epo all shared the same G6PD type, whereas the growth of epo-stimulated colonies of the nonclonal G6PD type indicated the presence of normal stem cells that had been repressed in vivo. Granulocytic colonies grown from stem cells separated from blood or bone marrow also demonstrated the coexistence of both normal and clonal progenitors. 66 In addition, the overwhelming majority of lymphoid lines (108 of 117) established from one patient produced the G6PD type characteristic of the PV clone. 67 In this patient, some but not all B lymphocytes derived from the PV clone.
ET and agnogenic myeloid metaplasia (AMM) were also shown by G6PD assays to be clonal disorders involving multipotent stem cells. 68, 69 As in PV, the vast majority of lymphoid lines established from one patient with ET shared the same enzyme type as the abnormal clone. 67 Cultured marrowderived fibroblasts from a patient with AMM were shown to be polyclonal. 70 That is, the bone marrow fibrosis was likely a secondary effect and not the primary problem as had been assumed by many. The findings in PV, ET and AMM were later confirmed using DNA markers. 71, 72 Methylation based DNA X-inactivation markers These and other studies using G6PD as a clonal marker generated interest in characterizing disease in a larger number of patients. Extension of the studies into a broader population requires the use of common and highly polymorphic markers. As first described for the hypoxanthine-phosphoribosyl transferase (HPRT) gene by Vogelstein et al, 73 DNA-based marker systems rely on a sequence polymorphism that has adjacent differences in methylation on the active and inactive X chromosomes. Inactive X chromosomes tend to be more highly methylated than their active homologues, but this is true only for certain regions of genes and is not well-maintained in other regions of genes or in intergenic sequences. In addition to HPRT, a DNA restriction fragment length polymorphism in phosphoglycerate kinase (PGK), 74 ,75 a variable length tandem repeat sequence in a non-expressed locus DXS255 (M27␤) 76 and a short tandem repeat polymorphism (STRP) in the human androgen receptor alpha (HUMARA) 77 have been extensively exploited. Among other problems, inconsistencies in methylation patterns limit the strength of conclusions based on some of these markers. 74, 78, 79 The HUMARA locus appears to maintain the stringent methylation differences required for reliability. Almost all women are heterozygous for the highly polymorphic STRP it contains. An added benefit is that, because it is performed by polymerase chain reaction amplification (PCR), small numbers of cells can be assayed.
Regardless of the marker used, information about the distribution of relative activity of the maternal and paternal X chromosomes between normal tissues in an individual and in the general population is needed for interpretation of results. In almost all hematopoietically normal G6PD heterozygous females studied, the ratio of A to B G6PD in blood cells has closely paralleled that in skin. 80 Only two out of 241 females without leukemia had granulocytes that expressed only a single G6PD type although both types were found in another tissue, such as skin or muscle. 81 With any marker of X-inactivation, some proportion of women will be within the area at the extremes of the binomial distribution and should be excluded from clonality studies. 25, 74, 82 Fialkow and his colleagues excluded from study those women whose ratios of Gd A to Gd B activity were severely skewed (unpublished data). Only half of these cases would be interpretable (ie those whose leukemic clone exhibit the minority G6PD type) and quantitative data would be limited in scope.
The expression-based and DNA methylation-based systems each have strengths and weaknesses. Both systems can detect a 5%:95% admixture and both are only informative for female patients. The greatest advantage of the DNA system is its nearly universal applicability. The greatest advantage of the G6PD system is the ability to study anucleate cells such as platelets and erythrocytes.
Myelodysplastic disorders
Like the myeloproliferative disorders, the myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders with respect to blood cell counts, marrow cellularity and prognosis (reviewed in Refs 83 and 84). The individual disorders exhibit varying degrees of anemia, neutropenia and thrombocytopenia. They have in common dysplastic cellular morphology, abnormalities of marrow cellular maturation and an increased probability of developing acute leukemia. Acquired chromosomal abnormalities are found in approximately 33-66% of patients with MDS. 85, 86 Analysis of G6PD and cytogenetics strongly suggested that a multipotent progenitor was involved in sideroblastic anemia in two patients. 87, 88 In addition to marrow cells, erythrocyte, granulocytes and platelets, 21 of 24 EBV-transformed lymphoid lines from one of these patients displayed the same G6PD type. In contrast, two cytogenetically unrelated abnormal cell populations were found along with cytogenetically normal cells in marrow. 88 These abnormalities, trisomy 8 and a rearrangement involving chromosome band 11q23, are recurrent changes in leukemias, 89 ,90 MDS 91 and MPD. 92 These observations and many other instances of late-appearing cytogenetic abnormalities or the presence of multiple abnormal cytogenetically distinct clones argue that MDS evolves by a multistep process. As is hypothesized for CML (eg Refs 93 and 94), an early step leads to proliferation of clonal pluripotent stem cells that are cytogenetically normal. Chromosomally abnormal subclones arise; some of these expand and contribute to the progression of disease. Failure to detect the chromosomal abnormality in lymphocytes by fluorescence in situ hybridization (FISH) had been used as an argument that the pluripotent stem cell is not affected in MDS. 95, 96 However, one case is particularly instructive. 97 A deleted chromosome 20, a recurrent cytogenetic abnormality in MPD 91 and MDS, 90 was identified by microsatellite PCR in purified blood granulocytes but not in lymphocytes. Using the DNA phosphoglycerate kinase (PGK) 112 marker system myeloid cells were shown to be clonal whereas the lymphocytes were polyclonal. Yet the same chromosomal abnormality found in myeloid cells was identified in some EBV-transformed B lymphoid lines. The majority of lymphocytes may not share the abnormal karyotype because they are long-lived and precede the acquisition of the alteration.
The clonal development and pluripotent stem cell origin of many cases of MPD and MDS have been substantiated by a number of DNA studies (eg Refs 98-100). In other cases a more differentiated myeloid-restricted stem cell was proposed to be involved. 74, 100 However, failure to detect a clonal marker in all cells of all lineages does not preclude multipotent stem cell involvement. Pluripotent neoplastic and residual normal stem cells may coexist and the ability of the neoplastic stem cell clone to differentiate and expand may be variably repressed in particular lineages.
Evidence for a multistep pathogenesis of acute leukemia
The many subtypes of acute myelogenous leukemia (AML) may, in turn, be preceded by any of the subtypes of MDS. This clinical diversity complicates the interpretation of data obtained in studies of small numbers of patients. As with the MPD and MDS, it was difficult to accumulate data from a sufficient number of G6PD-heterozygous patients for correlation across this clinical spectrum. Despite wide-spread collaboration, by 1981 only five G6PD-heterozygous patients with AML had been identified. Nevertheless, it was shown that AML also develops clonally and probably has a multistep pathogenesis. 101 The pattern of stem cell differentiative expression in acute phase is heterogeneous. In addition, marrow reconstitution in remission is variable in degree of clonal representation. Studies on an eventual total of 27 women were facilitated by the ability to assay significant numbers of erythroid and granulocytic colonies as well as anucleate cells using G6PD. 102 Remissions in AML are usually nonclonal. However, there are some cases in which hematopoiesis apparently remains clonal. [102] [103] [104] [105] [106] [107] In one illustrative case, during the acute leukemic phase 80% of marrow metaphase cells shared an abnormal karyotype and the marrow cells were clonal on the basis of G6PD. 103 A karyotypically normal remission that persisted for 6 months retained the clonal G6PD A phenotype. The failure to detect a 10% admixture of type B G6PD in acute phase suggests that the karyotypically normal cells seen at that time also belonged to the leukemic clone. These observations indicate the possibility of a clonal preleukemic phase in AML. Such a preleukemic phase may not be recognized in many patients because hematopoiesis is histologically normal, the patients are asymptomatic and/or the duration is very short. However, such a phase may provide a rationale for the curious occurrences of coexistence or sequential appearance of cytogenetically unrelated abnormal clones (eg .
Studies in childhood acute lymphoblastic leukemia (ALL) by Pui et al 111 support this unifying explanation. Three patients who each had two cytogenetically independent cell populations at diagnosis were heterozygous for an X-linked DNA marker. Three rearranged and one germ-line configuration TCR bands were found in leukemic cell DNA from one of these children. Yet, marrow from all three children showed clonal X-inactivation patterns. Perhaps there is a population of morphologically normal appearing marrow cells deriving from a clonal stem cell pool in which cytogenetically abnormal subclones arise. Some of these changes confer selective proliferative advantage and the subclone increases in size.
Represented among the cytogenetic changes in the cases reported are ones known to occur non-randomly in association with certain morphologic varieties of leukemia and to activate or alter the function of genes. One widely held hypothesis states that production of the altered gene product is both necessary and sufficient to cause the disease in a single step. However, as described for Ph-positive CML, there is evidence supporting a multistep pathogenesis for other disorders in which non-random chromosome changes occur. For example, colonies were studied during long-term remissions from ANLL in which the AML/ETO chimeric transcript was detected. 112 The translocation was expressed in a small fraction of granulocytic, erythrocytic, megakaryocytic and mixed colonies and cells in these colonies did not show maturation arrest. One possible interpretation is that the t(8;21)-containing multipotent progenitors are not necessarily fully transformed and that other mutational changes are required. Other investigators have also observed mature granulocytes containing cytogenetic abnormalities associated with a leukemia (eg Refs 104, 113 and 114). The frequent detection of minimal residual disease in acute leukemias, despite long-duration complete clinical remissions, 115 is consistent with the existence of a stage during which the chromosome translocationbearing cells are under some degree of repression. Evidence for transcription of a leukemia-associated fusion gene in hematopoietic cells of individuals without leukemia has also been found (eg MLL-AF4; Ref. 116). The specific chromosomal changes likely determine the differentiative expression of the stem cell involved by the leukemia and confer specificity to the disease. However, the effects that at least some of these alterations have on cell behavior may not be 'sufficient' to cause the acute leukemic phenotype in all cases.
Alternative interpretations have been proposed for the few instances of clonal-appearing remissions reported. Chemotherapy may have depleted the normal stem cell population so that hematopoiesis during remission in these cases is accomplished by only a few progenitors. In this case, it would be predicted that the clone in some remissions would be discordant from that seen during acute phase. Using G6PD or a DNA methylation-based marker, at least 13 patients with a clonal phenotype in hematopoietic cells during remission from AML have also been evaluated during acute phase. 102, [104] [105] [106] [107] 117 The observation that in all 13 cases the clonal phenotype in remission phases was the same as exhibited by the leukemic cells argues against stem cell depletion as the underlying mechanism. The probability that this occurred by chance alone is Ͻ0.0001 (1/2 13 ). Might the findings be the result of discordance in X chromosome activity patterns between the hematopoietic system and the tissue used as a control to determine the constitutional pattern? As described above, extreme discordance between tissues is rarely observed in normal individuals. However, it has been reported recently that hematopoietic cells show increasingly skewed patterns of X-chromosome activity with increasing age. 118 The ages of the 13 patients reported to have clonal remissions ranged from 2 to 67 years and five of the patients were 12 years old or younger, making this explanation unlikely as well.
In the past decade, many molecular events that contribute to the pathogenesis and progression of human neoplasia have been described. Regulation of cell proliferation, differentiation, maturation and apoptosis is very complex. Perturbation of one or a combination of the signaling pathways in primitive progenitors might result in clones that are not recognized. Mutation or loss of genes involved in the ordered pro-gression of the cell cycle, entry into the pathway of apoptosis and repair of damaged DNA have been found in a variety of neoplasms. [119] [120] [121] The simultaneous evaluation of diseaseextrinsic and disease-related markers is an increasingly more powerful approach to clarify the steps involved in this complicated process.
Conclusions
These studies by Phil Fialkow and his many collaborators on myeloproliferative, myelodysplastic and leukemic disorders contributed substantially to our understanding of the pathogeneses of these neoplasms. They recognized the importance of X-inactivation mosaicism as a marker of tumor development. The insightful questions they posed and investigated comprise an important part of the growing body of literature supporting the currently accepted hypothesis that hemopoietic neoplasms develop clonally by stepwise evolution. The use of extrinsic markers allowed questions to be asked about the state of hemopoiesis before a disease is clinically detectable. It also allowed delineation of the pathways an involved stem cell follows in differentiation. This information indicated branch points during the ontogeny of normal hemopoiesis as well, for example, the cell pluripotent for myeloid and lymphoid cells. Such a cell might be involved in biclonal myeloid/lymphoid leukemias and underlie the occurrence of lineage instability in leukemia. Activation or inactivation of a gene by point mutation, chromosome translocation or deletion may confer specificity to a disease, but may not be sufficient to 'cause' it. The proposal that one stage in the neoplastic process is clonal but clinically normal remains a viable hypothesis for continued investigation to explain phenomena such as late appearance of Ph 1 , Ph-negative blast crises in Phpositive CML, clonal remissions in AML and prolonged remissions despite persistent minimal residual disease.
